A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19
This is a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care, compared with placebo plus standard of care, in patients with respiratory signs and symptoms secondary to novel coronavirus disease (COVID-19).
- Cytokine Storm
- Cytokine Release Syndrome
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Accepts Healthy Volunteers
Type of Subject and Disease Characteristics
1. Documented or confirmed SARS-CoV-2 infection by an FDA-approved PCR test of nasopharyngeal swab or stool less than 72 hours before randomization.
2. Hospitalized for COVID-19.
3. Illness of any duration with at least one of the following
1. Clinical assessment (evidence of rales/crackles on exam) AND SpO2 less than or equal to 94% on room air, or
2. Requiring mechanical ventilation and/or supplemental oxygen, or
3. Radiographic evidence (chest x-ray or CT scan) of one of the following:
- Ground-glass opacities, or
- Local or bilateral patchy infiltrates, or
- Interstitial pulmonary infiltrates
4. If the subject is intubated, must have been intubated less than 24 hours prior to randomization.
Sex and Contraception Guidelines
5. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
6. Capable of giving signed informed consent or by a designated representative which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Subjects are excluded from the study if any of the following criteria apply:
1. Active bacterial pneumonia defined: based on either lobar consolidation on x-ray, positive sputum cultures, or leukocytosis with a left shift.
2. Known active tuberculosis (TB).
3. Subjects with acquired immune deficiency syndrome (AIDS).
4. It is not in the best interest of the subjects to participate, in the opinion of the treating Investigator.
5. In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
6. Female subjects who are pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the screening visit through 90 days after the last dose of study intervention.
Excluded Prior/Concomitant Therapy
7. Prior treatment with other agents with actual or possible direct acting anti inflammatory activity against SARS-CoV-2 in the past 30 days (e.g. chloroquine, hydroxychloroquine).
8. Treatment with convalescent plasma.
9. Treatment with high doses of corticosteroids (greater than 20 mg daily, prednisone equivalent) prior to randomization.
10. Treatment with immunomodulators including anti-IL 6, anti-IL-6 receptor antagonists, or with Janus kinase inhibitors (JAKi) in the past 30 days or plans to receive during the study period.
11. Previous exposure to study intervention or any other agent targeting CSF-1 or CSF 1R or known allergy/sensitivity to study intervention.
- Phase 2
- Study Type
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Double (Participant, Care Provider)
|Axatilimab on Days 1 and 15, IV + SOC||
|Matching placebo on Days 1 and 15 + SOC||
- Syndax Pharmaceuticals
Study ContactSue Fischer
Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody with high affinity against CSF-1R under investigation for the prevention or treatment of respiratory signs and symptoms secondary to novel coronavirus disease (COVID-19).
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of axatilimab as an add-on to standard of care (SOC) therapy in hospitalized subjects with respiratory signs and symptoms secondary to COVID-19 compared to SOC treatment.
Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment groups, active or control. All subjects will receive axatilimab or matching placebo intravenously (IV) as an add-on to SOC on Day 1, within 8 hours of randomization and on Day 15. Subjects will be followed for at least 28 days (+3 days) after the first dose of study intervention (Day 29).
The primary objective of the study is to assess the proportion of subjects alive and free of respiratory failure at Day 29.